THE BAD NEWS for medical societies is that long-standing general (not event-specific) support seems to be on the decline in the current regulatory environment. The good news is that pharmaceutical companies are shifting their attention to CME meetings. But obtaining commercial support for any initiative, including meetings, is an increasingly complicated process. “On a scale of one to 10, the difficulty of obtaining funding is now a 10!” says Colleen Hennessey, coordinator of specialty ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only unlock thePrinter-friendly, you'll also gain access to exclusive premium content.

Already registered? here.